Examples of founding and evolving leading LifeScience companies. November 2016

Transcription

1 Examples of founding and evolving leading LifeScience companies November 2016

2 Peter Pohl Born: in Salzburg Love: my wife and my two children (age 9&7) Education: Business Adminstration Serial entrepreneur Passion: Founding of companies, growth of companies, leadership, consultancy Place of Living: The Bodensee 2 IDEAHUB TRILAGO November 2016

3 The beginning 3 IDEAHUB TRILAGO November 2016

4 Foto Hinterhof Fritz-Arnold-Strasse 4 IDEAHUB TRILAGO November 2016

5 GATC Headquarter Konstanz 5 IDEAHUB TRILAGO November 2016

6 GATC Biotech Innovation management throughout the years New technologies allow better insights and deeper understanding of scientific requirements. 1 st NGS service provider Today GATC-Böxle TM World s first non-radioactive sequencing technology 1 st 24h sequencing service GATCLIQUID TM Realisation of personalised medicine Multiplatform (PacBio + HiSeq + MiSeq) 6 IDEAHUB TRILAGO November 2016

7 Our service workflow enables high-quality research Online platform Efficient logistic solutions Sequencing, assembly & analysis Customer Hotline; NextGen projects supervised by project management All tubes/plates carry barcode labels 7 IDEAHUB TRILAGO November 2016 Automated production processes Data delivery via secured mygatc account

8 Production: The power horses at GATC European Custom Sequencing Center, Cologne, Germany Genome and Diagnostic Centre, Constance, Germany Fastest Sanger sequencing service in Europe ISO accredited Swift logistics Overnight service Next-generation sequencing on all prevalent technologies INVIEW standardised NGS ISO / ISO Certified Service Provider of Illumina and PacBio ~ samples p.a. ~ samples p.a. 8 IDEAHUB TRILAGO November 2016

9 European wide sales and production structure We have subsidiaries, labs and sales offices in Germany (incl. Labs) Great Britain France Sweden and customers in over 30 countries 9 IDEAHUB TRILAGO November 2016

10 Product Portfolio: GATC Sequencing Solutions overview Sanger sequencing Next Generation Sequencing Flexibility in services, delivery times and batch size NightXpress TM Tubes or 96-well format LIFE TECHNOLOGIES HUMAN EXOME AMPLICON TRANSCRIPTOME EPIGENOME MODIFICATION ANALYSIS DE NOVO GENOME MICROBIOME Pacific Bioscience Pre-Sequencing Library Sequencing Bio-IT Illumina 10 IDEAHUB TRILAGO November 2016

11 Uniqueness of GATC Biotech GATC is the No. 1 Service Provider of DNA and RNA sequencing in Europe since 25 years Family owned business in the molecular diagnostics area Experience and loyalty of Management Excellent network in the academic and medical space with more then customers High reputation and strong, well-known brand GATC runs a profitable core business with strong upside opportunities in molecular diagnostics First-Mover experience (new technologies, LifeCodexx, Liquid Biopsy) Successful entry in the diagnostics market with LifeCodexx Scaling and optimizing processes in the molecular biology area Patents and proprietary processes & algorithms (GATC- LIMS, PraenaTest, PraenaBoxx) Accreditated processes with ISO 17025, ISO 13485, ISO 9001; Certified Service Provider of Agilent, Illumina and Pacific Biosciences; potential CAP/CLIA accreditation 11 IDEAHUB TRILAGO November 2016

12 GATCLIQUID The Liquid Biopsy Service Line of GATC

13 Limitations of tissue biopsy Biopsy is invasive May not be feasible based on patient condition or tumour accessibility Impractical for periodic monitoring for progression recurrence Biopsy tissue is often very limited Greater demand due to molecular profiling Surgery is costly Example Cancer: heterogeneous disease Molecular properties differ within tumours Therapy causes changes in tumour cells 13 IDEAHUB TRILAGO November 2016

14 The principle of liquid biopsy 14 IDEAHUB TRILAGO November 2016

15 Liquid Biopsy The X-Ray of the 21 st century Liquid Biopsy is non-invasive declining need for operations for diagnostic purpose Body fluids are easier and less costly to collect compared to solid biopsies Growing interest in research brings Liquid Biopsy in clinical environment Liquid biopsies have the potential to replace traditional invasive diagnostics methods that are often ineffective or nearly impossible to perform. By improving the outcome for cancer patients, liquid biopsy can ultimately become the X-ray of the 21st century. 15 IDEAHUB TRILAGO November 2016

16 GATCLIQUID: GATC s research services for cancer research and diagnosis ONCOEXOME ONCOPANEL ONCOTARGET Unbiased discovery Exome sequencing of matched samples from tumour tissue, cell-free DNA and blood Targeted screening Panel sequencing of clinically actionable mutations, including low frequency mutations Monitoring Frequent detection of single driver mutations after treatment, such as surgery or therapy 16 IDEAHUB TRILAGO November 2016

17 GATCLIQUID services follows the cancer treatment timeline Screening Diagnosis Treatment Follow-up STAGING SURGERY CHEMO RADIATION RECUPERATION Biopsy Imaging Tumour size Molecular stratification Tumour removal Irradiance Medication Monitoring GATCLIQUID Diagnosis ONCOEXOME Adjuvant treatment decision Companion diagnostics Measurement of therapeutic response Follow-up ONCOPANEL ONCOTARGET 17 IDEAHUB TRILAGO November 2016

18 LifeCodexx Establishing Market Leadership with Liquid Biopsy in Prenatal Diagnostics

19 Market Opportunity Non-invasive prenatal testing (NIPT) is the safest and most accurate option to test for genetic abnormalities during pregnancy 19

20 PrenaTest NGS NIPT for detection of fetal trisomies T21, T13, T18 and more First NIPT to enter the European market when it was launched in August 2012 following clinical validation Originally (at launch) focused on the detection of fetal trisomy T21; test capabilities have since been extended to detect T13, T18, gonosomal aneuploides and multiple pregnancies Only NIPT in Europe for the detection of the indicators listed above that is performed in accordance with the In-Vitro Diagnostics Directive 98/79/EG of the European Union (requires both CE-marked analysis software and a full quality assurance system) Utilizes Massively Parallel Sequencing (MPS), which is typically accepted as one of the best validated methods for NIPT Currently available in 35 countries across Europe, the Middle East and Asia Currently holds either the number one or two market position in all active territories Recently launched in Italy, Belgium, Serbia, Slovenia, Croatia, Macedonia, Montenegro, Ukraine, Greece, Portugal with ongoing launches in Russia, India, Vietnam and Spain Analysis includes the use of both LifeCodexx proprietary QuantYfeX assay (for quantification of fetal DNA at the beginning of the analysis) and PrenaTest DAP.plus analysis software (for bioinformatic analysis of the sequencing data) Applied for reimbursement in Germany and Switzerland submitted in 2013 and in Hungary in 2015; received statutory reimbursement in Switzerland in 2015 and Germany and Hungary are pending Initiated a Post Marketing Clinical Follow-Up (PMCF) study with the University of Bonn in Germany; aim is to determine the birth outcome of ~2,000 patients - more than 1,500 patients recruited to date 20

21 Challenges during Founding & Evolving Get the product DBE / Services / PrenaTest Get the investment Own money Customer Public funds Other people s money ( OPM ): VC / PE / Family Office / F&F Get the right team More important than product and money!! Get the customer the only one that brings in money (if you want to earn money) Get the grip Think first and then move, move, move Move the bottlenecks or they will move you 21 IDEAHUB TRILAGO November 2016

22 Thank you! 22 IDEAHUB TRILAGO November 2016